Envoy Medical Expands Patent Portfolio by Securing Additional European Patent for Breakthrough Cochlear Implant Technology
Envoy Medical (NASDAQ: COCH) has been granted European Patent No. 4338791 for its innovative cochlear implant technology, effective September 17, 2025. The patent specifically covers systems and methods for compensating for variability in middle ear sensors using analog and digital signals.
This patent adds to Envoy Medical's recent patent acquisitions in the United States, Australia, and Hong Kong. The technology relates to their investigational Acclaim® Cochlear Implant, which uniquely eliminates external microphones and hardware by leveraging the natural ear, potentially transforming treatment for severe to profound sensorineural hearing loss.
Envoy Medical (NASDAQ: COCH) ha ottenuto la Brevetto Europeo n. 4338791 per la sua innovativa tecnologia di impianto cocleare, con effetto dal 17 settembre 2025. Il brevetto copre specificamente sistemi e metodi per compensare la variabilità nei sensori dell'orecchio medio utilizzando segnali analogici e digitali.
Questo brevetto si aggiunge alle recenti acquisizioni brevettuali di Envoy Medical negli Stati Uniti, in Australia e a Hong Kong. La tecnologia è legata al loro sperimentale Acclaim® Cochlear Implant, che elimina in modo unico i microfoni esterni e l'hardware sfruttando l'orecchio naturale, con potenziali conseguenze trasformative per il trattamento della perdita uditiva neurosensoriale da moderata a grave.
Envoy Medical (NASDAQ: COCH) ha obtenido la Patente Europea No. 4338791 para su innovadora tecnología de implante coclear, con efecto a partir del 17 de septiembre de 2025. La patente cubre específicamente sistemas y métodos para compensar la variabilidad en los sensores del oído medio utilizando señales analógicas y digitales.
Esta patente se suma a las recientes adquisiciones de patentes de Envoy Medical en los Estados Unidos, Australia y Hong Kong. La tecnología se relaciona con su innovador Acclaim® Cochlear Implant, que elimina de forma única micrófonos externos y hardware al aprovechar el oído natural, lo que podría transformar el tratamiento de la pérdida auditiva neurosensorial de moderada a profunda.
Envoy Medical (NASDAQ: COCH)가 혁신적인 인공 와우 임플란트 기술에 대해 유럽 특허 4338791호를 2025년 9월 17일부터 유효하게 부여받았습니다. 이 특허는 아날로그 및 디지털 신호를 사용하여 중이 센서의 가변성을 보상하기 위한 시스템 및 방법을 구체적으로 다룹니다.
이 특허는 Envoy Medical의 최근 미국, 호주, 홍콩의 특허 획득에 더해집니다. 이 기술은 그들의 실험적 Acclaim® Cochlear Implant와 관련이 있으며, 외부 마이크로폰과 하드웨어를 독특하게 제거하고 자연스러운 귀를 활용함으로써 중등도에서 중증의 감각신경성 난청 치료를 혁신적으로 바꿀 수 있습니다.
Envoy Medical (NASDAQ: COCH) a obtenu le Brevet européen n° 4338791 pour sa technologie innovante d’implant cocléaire, en vigueur à partir du 17 septembre 2025. Le brevet couvre plus précisément des systèmes et des méthodes permettant de compenser la variabilité des capteurs de l’oreille moyenne en utilisant des signaux analogiques et numériques.
Ce brevet vient s’ajouter aux récentes acquisitions de brevets d’Envoy Medical aux États-Unis, en Australie et à Hong Kong. La technologie est liée à leur implant cocléaire expérimentaI Acclaim® Cochlear Implant, qui élimine de manière unique les microphones externes et le matériel en tirant parti de l’oreille naturelle, ce qui pourrait transformer le traitement de la perte auditive neurosensorielle de faible à sévère.
Envoy Medical (NASDAQ: COCH) hat Europäisches Patent Nr. 4338791 für seine innovative Cochlea-Implantat-Technologie erhalten, gültig ab dem 17. September 2025. Das Patent deckt speziell Systeme und Verfahren zur Kompensation von Variabilität in Mittelohrsensoren unter Verwendung analoger und digitaler Signale ab.
Dieses Patent ergänzt Envoy Medias jüngste Patenterwerbungen in den Vereinigten Staaten, Australien und Hongkong. Die Technologie bezieht sich auf ihr investigatives Acclaim® Cochlear Implant, das externen Mikrofone und Hardware einzigartig eliminiert, indem es das natürliche Ohr nutzt, und so die Behandlung von schweren bis hochgradigen sensorineuralen Hörverlust potenziell transformieren könnte.
Envoy Medical (NASDAQ: COCH) حصل على براءة الاختراع الأوروبية رقم 4338791 لتقنيته المبتكرة لجهاز الزرع القوقعي، والتي تسري فعاليتها اعتباراً من 17 سبتمبر 2025. تغطي البراءة على وجه التحديد الأنظمة والأساليب للتعويض عن التفاوت في مستشعرات الأذن الوسطى باستخدام إشارات تناظرية ورقمية.
تضيف هذه البراءة إلى الاستحواذات الأخيرة لشركة Envoy Medical في الولايات المتحدة وأستراليا وهونغ كونغ. ترتبط التقنية بجهازهم التجريبي Acclaim® Cochlear Implant، الذي يزيل بشكل فريد الميكروفونات الخارجية والأجهزة من خلال استغلال الأذن الطبيعية، ما قد يغير علاج فقدان السمع العصبي الحسي من متوسط إلى شديد.
Envoy Medical (NASDAQ: COCH) 已获得 欧洲专利号 4338791，用于其创新的耳蜗植入技术，自2025年9月17日起生效。该专利特别涵盖通过模拟与数字信号对中耳传感器的变量性进行补偿的系统与方法。
此专利是Envoy Medical在 美国、澳大利亚和香港 最近取得的专利之一。该技术与其研究中的 Acclaim® Cochlear Implant 相关，通过利用自然耳朵独特地消除外部麦克风与硬件，可能会改变中至重度感音神经性聋的治疗方式。
- None.
- None.
Insights
Envoy Medical strengthens its IP position in Europe with a patent for middle ear sensor signal processing, reinforcing its fully implanted cochlear technology strategy.
Envoy Medical has secured European Patent No. 4338791, effective September 17, 2025, bolstering its international intellectual property portfolio following similar recent approvals in the US, Australia, and Hong Kong. This patent specifically addresses sophisticated signal processing for middle ear sensors - a critical component of their technology strategy.
The patent focuses on systems that compensate for variability in middle ear sensors, using both analog and digital signals with adjustable digital filters to normalize frequency response. This is technically significant because it enables more reliable performance across different patients and implementation scenarios.
From a competitive standpoint, this patent strengthens Envoy's market position in fully implanted hearing technology. Unlike traditional cochlear implants that require external microphones and visible components, Envoy's investigational Acclaim® Cochlear Implant leverages the natural ear structure as the sound capture mechanism. This approach represents a paradigm shift in treating severe to profound sensorineural hearing loss.
The expanded patent protection is particularly valuable in the European medical device market, which is highly regulated and competitive. By securing these rights, Envoy creates barriers to entry for competitors while enhancing its freedom to operate in key markets. The timing aligns with their broader strategy of building a comprehensive intellectual property portfolio around their core technology.
For investors, patent expansions typically represent increased long-term value through market exclusivity and potential licensing opportunities. However, it's important to note that this patent alone doesn't guarantee commercial success, as regulatory approvals and market adoption remain separate challenges for their investigational devices.
Patent covers advanced signal processing for middle ear sensors, further advancing the Company's position in leveraging the ear for fully implanted hearing devices
White Bear Lake, Minnesota--(Newsfile Corp. - September 19, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced that it has received an Issue Notification from the European Patent Office and has been granted European Patent No. 4338791 which became effective September 17, 2025. The newly issued European patent strengthens Envoy Medical's global patent portfolio following recent issuances in the United States, Australia, and Hong Kong.
The title of the patent is "Implantable Cochlear System with Integrated Components and Lead Characterization" and relates to sophisticated systems and methods for compensating for variability in a middle ear sensor. Specifically, it covers the use of analog and digital signals from a middle ear sensor representing received stimulus signals. The digital filter can be adjusted to normalize the frequency response of the digitally filtered signals with respect to the stimulus signals.
"This latest patent reflects our continued innovation in fully implanted hearing technology that is designed to work with the body's natural anatomy. We believe these additional patents strengthen our position and continue to create shareholder value by expanding our global patent portfolio. We are not only protecting our groundbreaking innovations but also supporting our mission to deliver life-changing, fully implantable solutions to the people around the world who experience disabling hearing loss," said Brent Lucas, CEO of Envoy Medical.
Envoy Medical's fully implanted cochlear implant technology, including the investigational Acclaim® Cochlear Implant, is designed to eliminate the need for external microphones and wearable hardware, instead utilizing a sensor designed to leverage the natural ear. The company believes this technology represents a significant shift in the treatment paradigm for patients with severe to profound sensorineural hearing loss.
For more information about Envoy Medical's innovation pipeline and intellectual property portfolio, visit www.envoymedical.com.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operations; the ability to obtain additional patents, the ability to develop future products or product improvements, and the benefits of patents in protecting intellectual property; the Acclaim CI being the first to market fully implanted cochlear implant, the timing and results of approvals, site documents, logistics, activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI, and the participation or any changes in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: Envoy@kcsa.com
Media Contact:
Anne Donohoe
KCSA Strategic Communications
O: 732-620-0033
E: Envoy@kcsa.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/267047
FAQ
What is the new European patent granted to Envoy Medical (NASDAQ: COCH)?
How does Envoy Medical's Acclaim® Cochlear Implant differ from traditional cochlear implants?
In which countries does Envoy Medical (COCH) now hold patents for their cochlear implant technology?
What type of hearing loss does Envoy Medical's cochlear implant technology target?
What is the significance of Envoy Medical's middle ear sensor technology?
